Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia
Information source: Baylor College of Medicine
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Adrenal Hyperplasia, Congenital
Intervention: Hydrocortisone sodium acetate (Drug)
Phase: N/A
Status: Completed
Sponsored by: Baylor College of Medicine Official(s) and/or principal investigator(s): Morey W Haymond, MD, Principal Investigator, Affiliation: Baylor College of Medicine
Summary
The purpose of this study is to develop a more physiological approach to the management of
children and adolescents with salt wasting Congenital Adrenal Hyperplasia.
We will administer the glucocorticosteroid via insulin infusion pump to see whether this
treatment will improve the serum hormone concentrations.
Clinical Details
Official title: A Novel Therapeutic Modality for Congenital Adrenal Hyperplasia
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Serum 17-OHP concentration in the morning
Secondary outcome: serum steroid hormone profilesserum blood glucose serum sodium
Detailed description:
The adrenal gland is a small organ of the body. It produces very important chemicals called
hormones. One of these hormones, cortisol (the stress hormone) helps the body fight
diseases. The other hormone is the aldosterone helps to maintain the normal amount of salt
and water in the body. The third type of hormones are the androgens or male hormones, which
cause some of the changes during puberty, like the growth of body hair and pimples.
The salt wasting Congenital Adrenal Hyperplasia or CAH disease is a disease of the adrenal
gland. Patients with this disease cannot make cortisol or the aldosterone. As a result,
their body cannot fight diseases and cannot keep normal amounts of salt and water in the
body. At the same time, the gland makes too much of the male hormones, which is bad for the
body because too much male hormone slows down growth, increases the growth of body hair, and
causes pimples and abnormal period in girls.
Patients with this disease have to take medications every day. However, the treatment does
not work very well, because usually the patients do not have the right amount of hormone in
their body. Usually the body gets too much hormone right after taking the pills. A couple of
hours later the body has too little of the hormones, because in the meantime the body gets
rid of the medication. The healthy adrenal gland makes the hormones throughout the day in
different amounts. The patients with this disease take the medication only a couple of times
a day. They take the Florinef tablet once a day and the Cortisol tablet two or three times a
day. The treatment that we use today by mouth cannot copy the natural hormone productions of
the adrenal gland. Because of this it does not make much of a difference in the patient's
life.
We would like to improve the treatment and find out the effect of a new treatment. In this
study we will try to imitate the body's normal hormone production and will give the
medication via an insulin pump to see if this treatment method will decrease the male
hormones in the blood. This study will help us to develop a new and better treatment for
children and adolescents.
Eligibility
Minimum age: 3 Years.
Maximum age: 18 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Children with salt wasting CAH otherwise healthy without other chronic disease
- Age: between 3 and 18 years of age
- Body weight 23 kg (50 lbs) or above
- Hemoglobin equal to or higher than 12 g/dl before the study
- Supportive family environment
Exclusion Criteria:
- Age less than 3 or older than 18 years at the time of study
- Other chronic disease
- Hemoglobin less than 12 g/dl
- Non-supportive family
- Allergy to local anesthetics
Criteria for study termination: If the subject's parents are unable to manage/operate the
pump, the subject will be withdrawn from the study.
Locations and Contacts
BCM, Texas Children's Hospital Clinic and General Clinical Research Center, Houston, Texas 77030, United States
Additional Information
Related publications: Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC, Loriaux DL. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991 Jan;72(1):39-45. Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, Rogol AD. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab. 1993 Jun;76(6):1505-10. Speiser PW. Toward better treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 1999 Sep;51(3):273-4. Cutler GB Jr, Laue L. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med. 1990 Dec 27;323(26):1806-13. Review. Winterer J, Chrousos GP, Loriaux DL, Cutler GB Jr. Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. J Pediatr. 1985 Jan;106(1):137-42. Wallace WH, Crowne EC, Shalet SM, Moore C, Gibson S, Littley MD, White A. Episodic ACTH and cortisol secretion in normal children. Clin Endocrinol (Oxf). 1991 Mar;34(3):215-21. Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2006 Jul;65(1):45-50. Lukert BP. Editorial: glucocorticoid replacement--how much is enough? J Clin Endocrinol Metab. 2006 Mar;91(3):793-4. Erratum in: J Clin Endocrinol Metab. 2006 Jun;91(6):2073. Claude J.Migeon. Can the Long Range Results of the Treatment of Congenital Adrenal Hyperplasia be improved? JCEM 1996 Vol 81, No 9 3187-3189 Laue L, Merke DP, Jones JV, Barnes KM, Hill S, Cutler GB Jr. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1996 Oct;81(10):3535-9. Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, Tucker GT, Ross RJ. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2004 Sep;61(3):367-75. Sheila K.Gunn et al Subcutaneous Hydrocortisone Delivery mimics Physiologic Cortisol Concentrations, Poster, Endocrine Society Meeting 2000
Starting date: January 2007
Last updated: August 14, 2015
|